Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Imunon, Inc. filings document a Nasdaq-listed clinical-stage biotechnology issuer with common stock trading under IMNN and a business centered on non-viral DNA-mediated immunotherapy. The company's 8-K reports include financial results, business updates, clinical-program disclosures for IMNN-001 and the OVATION studies, and corporate events affecting executive roles and compensation arrangements.
Proxy and registration-related filings describe annual meeting matters, board and executive compensation governance, common-stock capital structure, and at-the-market equity offering arrangements. The filing record also includes Nasdaq listing-compliance disclosures and other public-company status reports tied to Imunon's financing, governance, and clinical-development operations.
Fritz Frederick J. reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. director Fritz Frederick J. received an equity compensation grant of 6,934 shares of Common Stock on 2026-07-31. The shares were granted in lieu of cash for a portion of his board fees at a value of $1.59 per share. Following this non-derivative, directly owned award, his reported Common Stock holdings increased to 21,031 shares.
Braun Donald P reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. director Donald P. Braun received a grant of 6,180 shares of common stock on July 31, 2026 at $1.59 per share, issued in lieu of cash for a portion of his board fees. Following this award, he directly holds 15,499 shares.
Susan Eylward, General Counsel and Corporate Secretary of Imunon, Inc., received a grant of 2,541 shares of common stock on July 31, 2026 in lieu of a portion of base salary at $1.59 per share, then sold 2,541 shares on August 3, 2026 at a weighted average of $1.5651 per share, within a $1.56-$1.575 range.
Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. granted its Executive Chairman Michael H. Tardugno 6,358 shares of common stock on July 31, 2026, valued at $1.59 per share, as stock in lieu of cash base salary, increasing his direct holdings to 75,357 shares plus 4,622 shares held indirectly through an IRA.
Faller Douglas Vincent reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. Chief Medical Officer Douglas Vincent Faller received a grant of 3,649 shares of common stock on July 31, 2026, valued at $1.59 per share. The shares were granted in lieu of cash for a portion of his base salary, increasing his direct holdings to 29,935 shares.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. President and CEO Stacy Lindborg reported a Form 4 showing a grant of 5,010 shares of Common Stock on July 31, 2026 at $1.59 per share, described as stock granted in lieu of cash for a portion of base salary. Following this award, she holds 86,639 shares directly and 778 shares indirectly through a 401(k) plan.
Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. executive chairman Michael H. Tardugno received a grant of 4,603 shares of common stock on July 17, 2026 at $1.83 per share, issued in lieu of cash base salary. Following this award he directly holds 68,999 shares, plus 4,622 shares held indirectly through an IRA.
Imunon, Inc. executive Susan Eylward, General Counsel and Corporate Secretary, reported two Common Stock transactions. On 2026-07-17, she received 2,150 shares at $1.8300 per share as stock granted in lieu of a portion of base salary. On 2026-07-20, she sold 2,150 shares at a weighted average price of $1.7816 per share, with individual sale prices ranging from $1.76 to $1.79. The filing indicates these trades were not made under a Rule 10b5-1 trading plan.
Faller Douglas Vincent reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. granted 3,082 shares of common stock to Chief Medical Officer Douglas Vincent Faller on July 17, 2026, valued at $1.83 per share. The stock was granted in lieu of cash for a portion of his base salary, and he now directly holds 26,286 shares of Imunon common stock.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. disclosed that President and CEO Stacy Lindborg received a grant of 4,907 shares of common stock on July 17, 2026 at $1.83 per share, issued in lieu of cash for a portion of her base salary. After this award she holds 81,629 shares directly and 778 shares indirectly through a 401(k) plan.